Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

2-Octadecynoic acid as a dual life stage inhibitor of Plasmodium infections and plasmodial FAS-II enzymes

Full text
Author(s):
Carballeira, Nestor M. [1] ; Bwalya, Angela Gono [2] ; Itoe, Maurice Ayamba [3] ; Andricopulo, Adriano D. [4] ; Cordero-Maldonado, Maria Lorena [5] ; Kaiser, Marcel [6, 7] ; Mota, Maria M. [3] ; Crawford, Alexander D. [5] ; Guido, Rafael V. C. [4] ; Tasdemir, Deniz [2, 8]
Total Authors: 10
Affiliation:
[1] Univ Puerto Rico, Dept Chem, San Juan, PR 00931 - USA
[2] Univ London, Sch Pharm, Dept Biol & Pharmaceut Chem, London WC1N 1AX - England
[3] Univ Lisbon, Inst Mol Med, P-1649028 Lisbon - Portugal
[4] Univ Sao Paulo, Inst Fis Sao Carlos, Ctr Pesquisa & Inovacao Biodiversidade & Farmacos, Lab Quim Med & Computac, BR-13563120 Sao Carlos, SP - Brazil
[5] Univ Luxembourg, Luxembourg Ctr Syst Biomed, Chem Biol Grp, L-4362 Esch Sur Alzette - Luxembourg
[6] Univ Basel, CH-4003 Basel - Switzerland
[7] Swiss Trop & Publ Hlth Inst, Dept Med Parasitol & Infect Biol, CH-4002 Basel - Switzerland
[8] Natl Univ Ireland, Sch Chem, Galway - Ireland
Total Affiliations: 8
Document type: Journal article
Source: Bioorganic & Medicinal Chemistry Letters; v. 24, n. 17, p. 4151-4157, SEP 1 2014.
Web of Science Citations: 5
Abstract

The malaria parasite Plasmodium goes through two life stages in the human host, a non-symptomatic liver stage (LS) followed by a blood stage with all clinical manifestation of the disease. In this study, we investigated a series of 2-alkynoic fatty acids (2-AFAs) with chain lengths between 14 and 18 carbon atoms for dual in vitro activity against both life stages. 2-Octadecynoic acid (2-ODA) was identified as the best inhibitor of Plasmodium berghei parasites with ten times higher potency (IC50 = 0.34 mu g/ml) than the control drug. In target determination studies, the same compound inhibited three Plasmodium falciparum FAS-II (PfFAS-II) elongation enzymes PfFabI, PfFabZ, and PfFabG with the lowest IC50 values (0.28-0.80 mu g/ml, respectively). Molecular modeling studies provided insights into the molecular aspects underlying the inhibitory activity of this series of 2-AFAs and a likely explanation for the considerably different inhibition potentials. Blood stages of P. falciparum followed a similar trend where 2-ODA emerged as the most active compound, with 20 times less potency. The general toxicity and hepatotoxicity of 2-AFAs were evaluated by in vitro and in vivo methods in mammalian cell lines and zebrafish models, respectively. This study identifies 2-ODA as the most promising antiparasitic 2-AFA, particularly towards P. berghei parasites. (C) 2014 Elsevier Ltd. All rights reserved. (AU)

FAPESP's process: 13/07600-3 - CIBFar - Center for Innovation in Biodiversity and Drug Discovery
Grantee:Glaucius Oliva
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC